Benzinga
Published Dec 20, 2023 16:00
Updated Dec 20, 2023 17:10
Understanding BioNTech's Position In Biotechnology Industry Compared To Competitors
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry out an in-depth industry comparison, assessing BioNTech (NASDAQ:BNTX) alongside its primary competitors in the Biotechnology industry. By meticulously examining key financial metrics, market positioning, and growth prospects, we aim to offer valuable insights to investors and shed light on company's performance within the industry.
BioNTech Background BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.
BioNTech SE | 8.67 | 1.17 | 3.57 | 0.81% | $0.27 | $0.24 | -74.13% |
AbbVie Inc | 42.08 | 22.42 | 4.94 | 14.25% | $4.74 | $7.44 | -5.97% |
Amgen Inc | 19.81 | 19.47 | 5.58 | 23.97% | $3.6 | $5.1 | 3.77% |
Vertex Pharmaceuticals Inc | 30.27 | 6.29 | 10.87 | 6.47% | $1.23 | $2.16 | 6.39% |
Gilead Sciences Inc | 17.03 | 4.44 | 3.66 | 10.03% | $3.23 | $5.49 | 0.11% |
Regeneron Pharmaceuticals Inc | 24.19 | 3.71 | 7.37 | 4.12% | $1.23 | $2.93 | 14.53% |
Biogen Inc | 25.02 | 2.52 | 3.66 | -0.47% | $0.05 | $1.87 | 0.87% |
Genmab A/S | 32.82 | 4.49 | 8.28 | 7.11% | $2.71 | $4.64 | 16.08% |
Biomarin Pharmaceutical Inc | 125.38 | 3.71 | 7.98 | 0.83% | $0.07 | $0.46 | 15.04% |
Incyte Corp | 32.93 | 2.81 | 3.87 | 3.54% | $0.26 | $0.86 | 11.63% |
Neurocrine Biosciences Inc | 63.94 | 5.96 | 6.85 | 4.31% | $0.12 | $0.49 | 28.59% |
United Therapeutics Corp | 13.25 | 1.98 | 5.40 | 4.81% | $0.38 | $0.54 | 18.1% |
Exelixis Inc | 82.21 | 3.16 | 4.36 | 0.04% | $-0.01 | $0.45 | 14.62% |
Average | 42.41 | 6.75 | 6.07 | 6.58% | $1.47 | $2.7 | 10.31% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } Through a detailed examination of BioNTech, we can deduce the following trends:
The debt-to-equity (D/E) ratio measures the financial leverage of a company by evaluating its debt relative to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, BioNTech stands in comparison with its top 4 peers, leading to the following comparisons:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.